Antibody cytokine fusion proteins against Cryptococcus neoformans
新型隐球菌抗体细胞因子融合蛋白
基本信息
- 批准号:7767749
- 负责人:
- 金额:$ 31.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-03-15 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdverse effectsAnimalsAntibodiesAntigen-Antibody ComplexAntigensBindingCellsCellular ImmunityCentral Nervous System InfectionsChemotherapy-Oncologic ProcedureChimeric ProteinsChronicCommunicable DiseasesComplement ActivationComplexCryptococcal MeningitisCryptococcus neoformansCryptococcus neoformans infectionDendritic CellsDiseaseDoseEffector CellEncapsulatedEquilibriumFc ReceptorGeneticGlobulinsGoalsGranulocyte-Macrophage Colony-Stimulating FactorGranulomatousHIVHIV InfectionsHalf-LifeHeatingHumanIgG3ImmuneImmune responseImmunityImmunocompromised HostImmunoglobulin GImmunoglobulin Variable RegionImmunotherapeutic agentInfectionInterleukin-12Interleukin-2KnowledgeLinkLungMalignant NeoplasmsModelingMusOrgan TransplantationOrganismPersonsPlayPolysaccharidesPopulations at RiskPreventionResearch PersonnelRheumatismRoleSiteSurfaceTalentsTestingTherapeuticTherapeutic UsesToxic effectVaccinationVaccine AdjuvantVaccinesYeastscapsulecytokinedesignefficacy testingexperienceflexibilityglucuronoxylomannanimmunogenicimprovedkillingsmortalitymouse modelnovelparacrinepathogenpractical applicationpreventprophylacticprotective efficacyreceptor bindingresponsetherapeutic vaccinetumoruptakevaccination strategy
项目摘要
DESCRIPTION (provided by applicant): Treatment with cytokines is moderately effective against mouse and human infection with Cryptococcus neoformans. However, systemic delivery of cytokines can be problematic for several reasons. Cytokines act in a local manner. Furthermore, they are rapidly degraded and side effects often limit their use. To overcome these limitations, we propose to construct and test several antibody-cytokine fusion proteins against C. neoformans infection with the goal of developing novel prophylactic and therapeutic vaccination strategies. For these fusion proteins, we will use an antibody specific for the outer capsule of C. neoformans, targeting cytokines directly to the site(s) of infection, while improving cytokine stability; thereby increasing the effective dose while decreasing systemic toxicities. There are currently no effective vaccines in use against C. neoformans. By linking cytokines to C. neoformans antigens, antibody-cytokine fusion proteins may be effective in generating protective immunity. Therefore, to test the efficacy of antibody-cytokine fusion proteins in preventing and treating C. neoformans infection, we propose: 1. To construct, produce and characterize antibody-cytokine fusion proteins specific for C. neoformans capsule. Antibody-cytokine fusion proteins consisting of the hinge-flexible human IgG3 against cryptococcal capsular polysaccharide genetically fused to either interleukin-2 (IL-2), granulocyte- macrophage colony stimulating factor (GM-CSF) or IL-12 will be produced recombinantly. Fusion proteins will be characterized for binding to C. neoformans as well as their functionality as cytokines and antibodies. 2. To determine the potential of antibody-cytokine fusion proteins to generate protective immunity to C. neoformans. Heat-killed C. neoformans or capsular polysaccharide will be opsonized with antibody- cytokine fusion proteins described above and administered to mice. Alternatively, dendritic cells will be loaded ex vivo with these immune complexes and delivered to mice. Host antibody and cellular immune responses specific for C. neoformans will be analyzed and protective efficacy of vaccination determined in mouse models of pulmonary and disseminated infection. 3. To determine the efficacy of cytokines genetically fused to antibody specific for C. neoformans capsule in cryptococcal infection. Antibody-cytokine fusion proteins will be given to mice with new or established infection to determine whether they can directly protect against disseminated cryptococcal infection. Host immune responses will be defined and correlated with efficacy. Mortality from cryptococcal meningitis is 10-20% indicating the need for better therapies. The population at risk for cryptococcal disease continues to grow due to increased survival of persons infected with HIV, new HIV infections, and the continued expansion of the number of persons with immunocompromise due to immuno- suppressive therapies for organ transplantation and rheumatic diseases as well as chemotherapy for cancer. The proposed studies have relevance beyond cryptococcal infection, since a significant long-term objective is to design antibody-cytokine fusion proteins for use in other types of infections.
描述(由申请方提供):细胞因子治疗对小鼠和人新型隐球菌感染中度有效。然而,由于几个原因,细胞因子的全身递送可能是有问题的。细胞因子以局部方式起作用。此外,它们迅速降解,副作用往往限制了它们的使用。为了克服这些局限性,我们提出了构建和测试几个抗体-细胞因子融合蛋白抗C。新型人感染,目的是开发新的预防性和治疗性疫苗接种策略。对于这些融合蛋白,我们将使用对C.新形式,直接将细胞因子靶向感染部位,同时改善细胞因子稳定性;从而增加有效剂量,同时降低全身毒性。目前还没有有效的疫苗用于C。新人类通过将细胞因子与C.新生儿抗原、抗体-细胞因子融合蛋白可有效产生保护性免疫。因此,为了检测抗体-细胞因子融合蛋白在预防和治疗C。我们提出:1.目的构建、制备和鉴定抗C.新囊抗体-细胞因子融合蛋白由抗隐球菌荚膜多糖的铰链柔性人IgG 3组成,与白细胞介素-2(IL-2)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)或IL-12基因融合,将重组产生。将表征融合蛋白与C.新型人以及它们作为细胞因子和抗体的功能。2.确定抗体-细胞因子融合蛋白对C.新人类热死C。将用上述抗体-细胞因子融合蛋白调理新生儿或荚膜多糖并给予小鼠。或者,树突状细胞将离体负载这些免疫复合物并递送至小鼠。宿主抗体和细胞免疫反应特异性C。将分析新生儿,并在肺部和播散性感染的小鼠模型中确定疫苗接种的保护效力。3.确定与C.隐球菌感染中的neoformans荚膜。将抗体-细胞因子融合蛋白给予具有新的或已建立的感染的小鼠,以确定它们是否可以直接保护免受播散性隐球菌感染。将定义宿主免疫应答并将其与疗效相关联。隐球菌脑膜炎的死亡率为10-20%,表明需要更好的治疗方法。由于HIV感染者的存活率增加、新的HIV感染以及由于器官移植和风湿性疾病的免疫抑制疗法以及癌症的化疗而导致的免疫功能低下的人数持续增加,处于隐球菌病风险中的人群继续增长。拟议的研究具有超越隐球菌感染的相关性,因为一个重要的长期目标是设计用于其他类型感染的抗体-细胞因子融合蛋白。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID Owen BEENHOUWER其他文献
DAVID Owen BEENHOUWER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID Owen BEENHOUWER', 18)}}的其他基金
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
住院 COVID-19 患者的多维结果预测算法
- 批准号:
10447721 - 财政年份:2021
- 资助金额:
$ 31.41万 - 项目类别:
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
住院 COVID-19 患者的多维结果预测算法
- 批准号:
10299344 - 财政年份:2021
- 资助金额:
$ 31.41万 - 项目类别:
Multi-Dimensional Outcome Prediction Algorithm for Hospitalized COVID-19 Patients
住院 COVID-19 患者的多维结果预测算法
- 批准号:
10656282 - 财政年份:2021
- 资助金额:
$ 31.41万 - 项目类别:
Enhancing the Delivery of Amphotericin B Across the Blood Brain Barrier for Treatment of Cryptococcal Meningoencephalitis
增强两性霉素 B 穿过血脑屏障的递送以治疗隐球菌性脑膜脑炎
- 批准号:
10265385 - 财政年份:2018
- 资助金额:
$ 31.41万 - 项目类别:
Enhancing the Delivery of Amphotericin B Across the Blood Brain Barrier for Treatment of Cryptococcal Meningoencephalitis
增强两性霉素 B 穿过血脑屏障的递送以治疗隐球菌性脑膜脑炎
- 批准号:
9898292 - 财政年份:2018
- 资助金额:
$ 31.41万 - 项目类别:
Enhancing the Delivery of Amphotericin B Across the Blood Brain Barrier for Treatment of Cryptococcal Meningoencephalitis
增强两性霉素 B 穿过血脑屏障的递送以治疗隐球菌性脑膜脑炎
- 批准号:
9446257 - 财政年份:2018
- 资助金额:
$ 31.41万 - 项目类别:
Antibody cytokine fusion proteins against Cryptococcus neoformans
新型隐球菌抗体细胞因子融合蛋白
- 批准号:
7383656 - 财政年份:2008
- 资助金额:
$ 31.41万 - 项目类别:
Antibody cytokine fusion proteins against Cryptococcus neoformans
新型隐球菌抗体细胞因子融合蛋白
- 批准号:
8015629 - 财政年份:2008
- 资助金额:
$ 31.41万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 31.41万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 31.41万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 31.41万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 31.41万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 31.41万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 31.41万 - 项目类别:
Discovery Grants Program - Individual